Listen
COSENTYX (secukinumab) - Psoriatic arthritis
Opinions on drugs -
Posted on
Mar 21 2024
Reason for request
Modification of the listing conditions
Key points
Favourable opinion for maintenance of reimbursement in the MA indication: “COSENTYX, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.”
Clinical Benefit
| Moderate |
The Committee deems that the clinical benefit of COSENTYX 150 mg and 300 mg (secukinumab) solution for injection in pre-filled syringe and pen remains moderate in this MA indication. |
Clinical Added Value
| no clinical added value |
In the absence of:
the Committee deems that COSENTYX 150 mg and 300 mg (secukinumab) solution for injection in pre-filled syringe and pen provide no clinical added value (CAV V) in the current care pathway, which includes the relevant comparators. |
English version
Contact Us
Évaluation des médicaments
